This retrospective analysis sought to determine the comparative incidence of cross-reactivity associated with carbapenem antibiotic treatment among patients with versus those without penicillin allergy. We sought to determine whether the incidence of cross-reactivity is different between imipenem-cilastatin and meropenem. A total of 211 patients were treated with a carbapenem antibiotic. Included were 100 patients with and 111 patients without a documented or reported penicillin allergy. Within each group, subgroups of penicillinallergic and penicillin-nonallergic patients were balanced equally between imipenem-cilastatin and meropenem. The incidence of patients with a reported or documented penicillin allergy experiencing an allergic-type reaction to a carbapenem was 11%, which is 5.2 times greater than the risk in patients who were reportedly not allergic to penicillin ( ). No difference in the occurrence of allergic-type reactions was observed between the P p .024 2 carbapenems.
The penicillins, cephalosporins, and carbapenems each possess the characteristic bicyclic core structure, the chemical entity believed to be most responsible for b-lactam hypersensitivity. An increased risk of hypersensitivity reactions with cephalosporins in penicillin-allergic patients has been well documented [1] . Imipenem-cilastatin, meropenem, and ertapenem make up the currently marketed carbapenem class of antibiotics. The incidence of carbapenem-associated hypersensitivity in the general population is estimated to be !3% [2] [3] [4] . As with cephalosporins, a significant risk for cross-hypersensitivity has been observed between penicillins and carbapenems [5, 6] . Thus, when challenged with a carbapenem, patients with a penicillin allergy are thought to be at higher risk for an allergic reaction than are those with no history of allergy to penicillin. The incidence of imipenemcilastatin hypersensitivity reactions among individuals with a reported or documented penicillin allergy has been reported to be 9.5%-25% [5, 6] .
The aim of our study was to determine the comparative incidence of cross-reactivity associated with carbapenem antibiotic treatment among patients with a documented or reported penicillin allergy, compared with a control group of patients without a documented or reported history of allergy to penicillin. The purpose of this study was to provide practical information to allow clinicians to make better-informed decisions regarding the choice of antibiotics in patients who report a history of allergy to penicillin, because the prescriber must frequently rely on self-reported allergy history.
PATIENTS AND METHODS
The study was reviewed and approved by the University of Michigan Health System's (Ann Arbor) institutional review board. All patients admitted to the University of Michigan Medical Center and treated with a carbapenem antibiotic during the period of 1 January 1999 through 31 August 2002 were eligible for inclusion in the study. An electronic medical record review identified and selected a total of 272 patients treated with a carbapenem antibiotic: 136 patients with a documented or reported penicillin allergy (group 1), and 136 patients without such allergies (group 2). Because nonimmunologic mediated drug rashes to ampicillin or amoxicillin and gastrointestinal disturbances to amoxicillin-clavulanate are often reported as allergic reactions, patients whose penicillin allergy was associated with ampicillin, ampicillin-sulbactam, amoxicillin, or amoxicillin-clavulanate were not included in the initial patient stratification [7] . Within each group, patients with or without a documented or reported penicillin allergy were equally balanced between treatment with imipenemcilastatin and meropenem. Ertapenem was not included in this study because it was not a formulary medication at this institution during the study period. Patients were excluded if they had undergone penicillin desensitization within 4 weeks of receiving therapy with a carbapenem, were treated with a penicillin concurrently or within 72 h before initiation of the carbapenem, had !72 h of follow-up after the first administered carbapenem dose, or failed to receive у1 dose of the prescribed carbapenem. An allergic-type reaction to imipenem-cilastatin and meropenem was defined as у1 of the following reactions: dermatologic reactions (such as rash or hives), fever, anaphylaxis, angioedema, hematological abnormalities (such as thrombocytopenia or leukopenia), or any other signs and symptoms deemed to be allergic in nature presenting after the initiation of therapy. Because eosinophilia may be the result of numerous causes, and because its occurrence is often benign, this manifestation was included as an allergic-type reaction only if it resulted in discontinuation of carbapenem therapy [8] . A causal relationship can be difficult to ascertain for certain reactions, such as drug-related fever and neutropenia, which may be immunologic and nonimmunologic in nature. To attempt to differentiate an immunologic and nonimmunologic reaction, a causal relationship was established, taking into account time to onset and the presence of other presumed causative factors.
Reactions deemed allergic in nature were documented on the basis of the classification scheme previously used by McConnell et al. [6] (table 1) . If an allergic-type reaction was noted, signs and symptoms, time to onset, and time to resolution were collected. Patient characteristics collected included age, sex, history of drug allergy, historical and current disease states, and concomitant medications. The duration of carbapenem therapy was also noted (table 2) . Demographic, clinical, and outcome data were compared among patients with and without a reported history of penicillin allergy by Fisher's exact test for categorical variables and by the Wilcoxon rank sum test for continuous variables. A logistic regression model was used to determine the adjusted odds of developing an allergic-type reaction to carbapenem therapy between groups 1 and 2.
was considered to be statistically signif-P ! .05 icant for all analyses. All statistical analyses were performed with SAS for Windows, release 8.02 (SAS Institute).
RESULTS
Of the 272 medical records that were initially identified for review, 35 were unavailable and 24 did not meet inclusion criteria. Of the 24 excluded patients, 13 patients had less than the required 72-h follow-up, and for 9 patients, an order was written but the patient did not actually receive the carbapenem. Finally, 2 patients were treated concomitantly with a penicillin. The remaining 211 patients were included in the analysis, 100 of whom had a documented or reported penicillin allergy, and 111 of whom did not. The results of immunologic tests for confirmation of presumed hypersensitivity was not reported for any of the patients with a reported or documented penicillin allergy.
Patients' demographic characteristics, the carbapenem used, the duration of carbapenem treatment, drug allergy history, and concomitant antibiotic and corticosteroid therapy are presented in table 2. There was a significantly higher proportion of men in group 2 than in group 1. Patients with a documented or reported penicillin allergy were more likely to have reported allergies to other antibiotics than were those with no reported or documented history of penicillin allergy. With the exception of concomitant fluoroquinolone treatment, no differences were noted in terms of either concomitant antibiotics or corticosteroids (у10 mg prednisone equivalent) used across the 2 cohorts. The overall incidence of carbapenem allergic-type reactions among the 100 patients in group 1 was 11% (11 of 100 patients), compared with an incidence of 2.7% (3 of 111 patients) in group 2 ( ). The mean times to reaction in patients P p .024 with and without a reported or documented penicillin allergy were 6.1 days (18 doses) and 3.7 days (11 doses), respectively. When comparing the incidence of carbapenem allergic-type reactions classified as definite or likely, excluding reactions deemed probable in nature, 8 (8%) of 100 patients in group 1 and 2 (1.8%) of 111 patients in group 2 were deemed to be allergic to carbapenems ( ). Five of these 8 reactions P p .0495 were specifically classified as definite in nature, but no reaction in group 2 could be classified as such ( ) (table 3) . P p .0227 When adjusting for age, sex, and prednisone use of у10 mg, the odds that a patient reporting a penicillin allergy would experience an allergic-type reaction to a carbapenem compared with the control group was 5.2 (95% CI, 1.4-20.0). Of the 9 penicillin-nonallergic patients with cephalosporin allergy, only 1 patient experienced a reaction. Among patients without a penicillin or cephalosporin allergy but with an allergy to у1 other antibiotic ( ), there were no observed allergic ren p 13 actions to carbapenems.
In summary, of the 3 reactions that occurred in penicillinnonallergic patients ( ), 2 occurred in patients who ren p 111 ported no antibiotic allergies, and 1 occurred in a patient who reported a cephalosporin allergy. The presence of cephalosporin allergy, the interaction of cephalosporin allergy and penicillin allergy, and the presence of noncephalosporin or nonpenicillin allergies were not significant predictors of a hypersensitivity reaction when added to the model. Therefore, these parameters were not included in the final model. In a separate analysis, when controlling for the total number of reported antibiotic allergies (not including penicillin) in addition to age, sex, and prednisone use, the presence of penicillin allergy remained the lone significant predictor. Inclusion of a total number of reported antibiotic allergies and presence of penicillin allergy interaction term also proved nonsignificant. A total of 19 reactions were observed in the 14 patients who reacted when treated with a carbapenem (table 4). The majority (10 of 19) of the reactions noted in this study were either rash or hives. The second most common reaction, drug fever, was seen in 3 patients. Respiratory distress and/or wheezing were seen in 2 patients, and arthralgia, neutropenia, and acute renal failure were each noted once. In addition, 1 patient with a history of rash to penicillin experienced an anaphylactic reaction when treated with the carbapenem.
Among the 101 imipenem-cilastatin-treated patients included in this study, 8 experienced reactions deemed allergic in nature. Meanwhile, a reaction was seen in 6 of 110 meropenem-treated patients (7.9% vs. 5.5%;
). Among P p .5833 patients with a documented or reported penicillin allergy, 6 of 49 imipenem-cilastatin recipients experienced an allergic-type reaction, as did 5 of the 51 patients who received meropenem (12% vs. 10%;
). Thus, with respect to the reaction P p .7575 rate between these 2 agents, no significant difference could be detected.
DISCUSSION
In the setting of a retrospective chart review, it is often difficult to determine whether a patient is truly allergic to penicillin. For instance, nonimmunologic drug rashes to ampicillin or amoxicillin and adverse gastrointestinal disturbances to amoxicillin-clavulanate are often reported as allergic reactions. In addition, penicillin hypersensitivity reactions that occurred several decades ago with less purely manufactured products may be less clinically relevant today. It has been reported that as many as 80%-90% of patients who report a penicillin allergy are not truly allergic [9, 10] . Because of the overall infrequency of skin testing and its limited value in predicting non-IgEmediated reactions [11] , the practitioner's choice of antibiotic therapy is often guided by patient self-report and allergy documentation in the medical record. We designed a retrospective analysis investigating the rate of cross-hypersensitivity between penicillins and the structurally similar carbapenem antibiotics among patients with a documented or reported penicillin allergy and compared this incidence with a reportedly nonallergic control group.
It has been reported that, when compared with patients who are not allergic to penicillin, patients with a penicillin allergy are 3 times more likely to experience an adverse reaction to other medications, regardless of whether the medication is chemically related [11] . It is therefore possible that multipledrug allergy is an independent risk for carbapenem allergy, which could have biased our results. In our study, patients with a history of a reported or documented penicillin allergy appeared to demonstrate an 11% incidence of hypersensitivity when treated with a carbapenem, compared with an incidence of 2.7% for patients without a reported history of penicillin allergy. Thus, patients with a documented penicillin allergy in their medical record and those who reported a history of such a reaction appear to have a 5-fold greater risk for developing an allergic-type reaction when treated with a carbapenem compared with those without such a history. Three of the 11 patients in group 1 who had a reaction were also reportedly allergic to cephalosporins, whereas 1 of the 3 in group 2 had a reported or documented allergic history to this class of antibiotics. This difference was deemed insignificant. In addition, there appeared to be no difference in the reaction rate between the 2 carbapenems assessed, imipenem-cilastatin and meropenem.
Saxon et al. [5] studied 40 subjects with documented IgE antibody to penicillin determinants for allergic cross-reactivity with imipenem-cilastatin by in vivo skin testing. The incidence of allergic cross-reactivity among subjects with a true penicillin allergy, as defined by skin testing, was determined to be 47% (9 of 19 patients), whereas the total incidence of cross-reactivity in all study subjects reporting a penicillin allergy (those with positive and negative penicillin skin test results) was 25% (10 of 40 patients). A second study, a retrospective medical record review conducted by McConnell et al. [6] , evaluated the incidence of imipenem-cilastatin hypersensitivity reactions in febrile neutropenic bone marrow transplant recipients with a history of penicillin allergy. Six of the 63 patients included in this study were classified as having a documented allergy to penicillin in which a reaction was documented or witnessed by a health care professional during a previous hospital admission. The remaining 57 patients were classified as having self-reported allergies. The incidence of allergic reactions among patients classified as having a documented allergy was 33% (2 of 6 patients), whereas the incidence among those with a self-reported allergy was only 7% (4 of 57 patients). The overall incidence of imipenem-cilastatin allergy among the 63 patients in the study was 9.5%. The variability of results between these 2 studies compelled us to conduct our own retrospective analysis. Our results indicated a carbapenem hypersensitivity rate of 11% for those with a reported/ documented penicillin allergy, a rate that correlated well with that reported by McConnell et al. [6] . Because of its retrospective design, our study had certain inherent limitations. Interpretation of data collected retrospectively is typically less reliable than prospective evaluation, because retrospective analysis relies on accuracy and completeness of documentation in the medical record. It was often difficult to assess historical allergy information retrospectively, because information regarding the causative penicillin, reaction date, the nature of such reactions, and whether the reaction was initially reported by the patient or documented by a health care professional was often absent. It cannot be said with certainty that each patient included in the penicillinallergic group was truly allergic to penicillin. Indeed, data exist that suggest that the majority of patients who report a penicillin allergy are actually not allergic [9, 10] . It was also sometimes difficult to establish a temporal relationship between administration of the carbapenem and the allergic manifestations-and, if one could be established, to decipher whether the reaction was immunologically mediated. Thus, despite assiduously following study guidelines, the incidence of cross-hypersensitivity between penicillins and carbapenems may have been either underestimated or overestimated. The study would have been greatly strengthened by a prospective approach. This method would have allowed a more accurate assessment of historical allergic status through direct patient interview and would have allowed direct observation of the allergic reaction documented in the patient chart.
Prescribers must frequently rely on a patient's self-reported allergy history. This study represents the information that is most often available in true patient-care situations. As such, this article provides at least a modicum of practical information to clinicians. In this series, patients with a reported or documented penicillin allergy demonstrated an 11% incidence of carbapenem reactivity and appear to be at a 5-fold greater risk for an allergic-type reaction than are patients without a documented or reported history of penicillin allergy. The incidence of cross-hypersensitivity between penicillins and the carbapenem antibiotics appears to be clinically significant. However, because cross-hypersensitivity refers to a specific immunologic definition that otherwise cannot be definitively confirmed, a prospective evaluation including immunological testing is needed to truly quantify this relationship.
Clinicians should be cautious whenever imipenem-cilastatin or meropenem is administered to patients who are allergic to penicillin, especially if the penicillin-allergic reaction was documented by a health care professional. One must weigh the benefits and risks that accompany treatment and choose whether therapy with carbapenem antibiotics is indicated.
